<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278457</url>
  </required_header>
  <id_info>
    <org_study_id>2017021</org_study_id>
    <nct_id>NCT03278457</nct_id>
  </id_info>
  <brief_title>Risk Stratification Using PET in HCM</brief_title>
  <acronym>HCM-PET</acronym>
  <official_title>Risk Stratification Using Positron Emission Tomography (PET) in Hypertrophic Cardiomyopathy (HCM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Gävleborg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Landstinget i Värmland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalarna County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Gävleborg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall rationale is to reduce the risk of sudden cardiac death in individuals with
      hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron
      Emission Tomography (PET) findings to ventricular arrhythmias detected by the implantable
      cardioverter defibrillator (ICD). This could potentially lead to an improved risk
      stratification of HCM patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron Emission Tomography (PET) is a functional imaging technique that utilizes
      radioactive tracers to gain information on physiological or pathophysiological processes in
      vivo. Different tracers can provide information on different processes of interest. In
      cardiology, metabolic processes consuming oxygen (aerobic) can be studied with
      11-Carbon-Acetate, sympathetic innervation can be studied with 11-Carbon-hydroxyephedrine and
      using 15-Oxygen-water the myocardial blood flow. Structural information of the heart such as
      left ventricular mass, left ventricular volumes and wall thickness can also be calculated
      with PET.

      The aim is to correlate PET parameters and burden of ventricular arrhythmias in order to
      improve risk stratification in HCM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">June 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs myocardial blood flow</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter Myocardial blood flow (MBF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs ejection fraction</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter ejection fraction (EF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs mass</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs wall thickness</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter wall thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs oxygen consumption</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter oxygen consumption (MVO2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs sympathetic innervation</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter sympathetic innervation (retention index)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs myocardial external efficiency</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter myocardial external efficiency (MEE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia (VT) vs stroke work</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Ventricular tachycardia vs positron emissions tomography parameter stroke work (SW)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs myocardial blood flow</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter myocardial blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs ejection fraction</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter ejection fraction (EF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs mass</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs wall thickness</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs oxygen consumption</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter oxygen consumption (MVO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs sympathetic innervation</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter sympathetic innervation (retention index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs myocardial external efficiency</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter myocardial external efficiency (MEE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation (AF) vs stroke work</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>Atrial fibrillation vs positron emissions tomography parameter stroke work (SW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial size vs ventricular tachycardia</measure>
    <time_frame>History of VT since receiving an implantable defibrillator within last 15 years</time_frame>
    <description>atrial diameter, volume vs ventricular tachycardia</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Positron Emission Tomography</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypertrophic cardiomyopathy (HCM) and an implantable defibrillator (ICD)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertrophic cardiomyopathy, implantable cardioverter defibrillator, informed consent

        Exclusion Criteria:

          -  Patients younger than 18 years, pregnancy, breast feeding, claustrophobia,
             intolerance/allergic reaction to adenosin or mannitol, severe hypotension, unstable
             angina pectoris, incompensated systolic heart failure, increased intracranial
             pressure, hypovolemia, dipyramidole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jens Sörensen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Gävleborg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Magnusson, MD</last_name>
    <phone>+46705089407</phone>
    <email>peter.magnusson@regiongavleborg.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonny Nordström, MSc</last_name>
    <phone>+46725727670</phone>
    <email>jonny.nordstrom@regiongavleborg.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Region Gavleborg</name>
      <address>
        <city>Gävle</city>
        <zip>80324</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Magnusson, M.D.</last_name>
      <phone>+46705089407</phone>
      <email>peter.magnusson@regiongavleborg.se</email>
    </contact>
    <contact_backup>
      <last_name>Jonny Nordström, MSc</last_name>
      <phone>+46725727670</phone>
      <email>jonny.nordstrom@regiongavleborg.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29.</citation>
    <PMID>25173338</PMID>
  </reference>
  <reference>
    <citation>Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000 Aug 22;102(8):858-64.</citation>
    <PMID>10952953</PMID>
  </reference>
  <reference>
    <citation>Timmer SA, Germans T, Götte MJ, Rüssel IK, Dijkmans PA, Lubberink M, ten Berg JM, ten Cate FJ, Lammertsma AA, Knaapen P, van Rossum AC. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):779-88. doi: 10.1007/s00259-009-1350-3. Epub 2010 Jan 13.</citation>
    <PMID>20069294</PMID>
  </reference>
  <reference>
    <citation>Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003 Mar 19;41(6):987-93.</citation>
    <PMID>12651046</PMID>
  </reference>
  <reference>
    <citation>Timmer SA, Germans T, Götte MJ, Rüssel IK, Lubberink M, Ten Berg JM, Ten Cate FJ, Lammertsma AA, Knaapen P, van Rossum AC. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury. Am J Cardiol. 2011 May 15;107(10):1522-8. doi: 10.1016/j.amjcard.2011.01.029. Epub 2011 Mar 4.</citation>
    <PMID>21377644</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertrophic cardiomyopathy</keyword>
  <keyword>implantable cardioverter defibrillator</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

